{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:13:06Z","timestamp":1785427986629,"version":"3.56.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ovarian cancer is the most lethal gynecologic malignancy with an overall cure rate of merely 30%. Most patients experience recurrence within 12\u201324 months of cure and die of progressively chemotherapy-resistant disease. Thus, more effective anti-ovarian cancer therapies are needed. Here, we investigate the possibility of repurposing antibiotic monensin as an anti-ovarian cancer agent. We demonstrate that monensin effectively inhibits cell proliferation, migration and cell cycle progression and induces apoptosis of human ovarian cancer cells. Monensin suppresses multiple cancer-related pathways including Elk1\/SRF, AP1, NF\u03baB and STAT and reduces EGFR expression in ovarian cancer cells. Monensin acts synergistically with EGFR inhibitors and oxaliplatin to inhibit cell proliferation and induce apoptosis of ovarian cancer cells. Xenograft studies confirm that monensin effectively inhibits tumor growth by suppressing cell proliferation through targeting EGFR signaling. Our results suggest monensin may be repurposed as an anti-ovarian cancer agent although further preclinical and clinical studies are needed.<\/jats:p>","DOI":"10.1038\/srep17523","type":"journal-article","created":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T09:59:25Z","timestamp":1449482365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Antibiotic monensin synergizes with EGFR inhibitors and oxaliplatin to suppress the proliferation of human ovarian cancer cells"],"prefix":"10.1038","volume":"5","author":[{"given":"Youlin","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengjian","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianggong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengli","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam K.","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fugui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rex C.","family":"Haydon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hue H.","family":"Luu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong-Chuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangdan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,7]]},"reference":[{"key":"BFsrep17523_CR1","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrc2644","volume":"9","author":"RC Bast Jr.","year":"2009","unstructured":"Bast, R. C., Jr., Hennessy, B. & Mills, G. B. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9, 415\u2013428 (2009).","journal-title":"Nat Rev Cancer"},{"key":"BFsrep17523_CR2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","volume":"34","author":"RJ Kurman","year":"2010","unstructured":"Kurman, R. J. & Shih, Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34, 433\u2013443 (2010).","journal-title":"Am J Surg Pathol"},{"key":"BFsrep17523_CR3","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/PAT.0b013e328348a6e7","volume":"43","author":"WG McCluggage","year":"2011","unstructured":"McCluggage, W. G. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 43, 420\u2013432 (2011).","journal-title":"Pathology"},{"key":"BFsrep17523_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/PAT.0b013e32835f2264","volume":"45","author":"D Lim","year":"2013","unstructured":"Lim, D. & Oliva, E. Precursors and pathogenesis of ovarian carcinoma. Pathology 45, 229\u2013242 (2013).","journal-title":"Pathology"},{"key":"BFsrep17523_CR5","doi-asserted-by":"publisher","first-page":"7419","DOI":"10.1038\/ncomms8419","volume":"6","author":"TA Ince","year":"2015","unstructured":"Ince, T. A. et al. Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nat Commun 6, 7419 (2015).","journal-title":"Nat Commun"},{"key":"BFsrep17523_CR6","doi-asserted-by":"publisher","first-page":"x118","DOI":"10.1093\/annonc\/mds315","volume":"23,","author":"FA Raja","year":"2012","unstructured":"Raja, F. A., Chopra, N. & Ledermann, J. A. Optimal first-line treatment in ovarian cancer. Ann Oncol 23, Suppl 10, x118\u2013127 (2012).","journal-title":"Ann Oncol"},{"key":"BFsrep17523_CR7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.tips.2013.06.005","volume":"34","author":"SC Gupta","year":"2013","unstructured":"Gupta, S. C., Sung, B., Prasad, S., Webb, L. J. & Aggarwal, B. B. Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci 34, 508\u2013517 (2013).","journal-title":"Trends Pharmacol Sci"},{"key":"BFsrep17523_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tips.2013.11.002","volume":"35","author":"ZY Wang","year":"2014","unstructured":"Wang, Z. Y., Quan, Y. & Zhang, H. Y. Medical genetic inspirations for anticancer drug repurposing. Trends Pharmacol Sci 35, 1\u20133 (2014).","journal-title":"Trends Pharmacol Sci"},{"key":"BFsrep17523_CR9","first-page":"1283","volume":"27","author":"BC Pressman","year":"1968","unstructured":"Pressman, B. C. Ionophorous antibiotics as models for biological transport. Fed Proc 27, 1283\u20131288 (1968).","journal-title":"Fed Proc"},{"key":"BFsrep17523_CR10","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1158\/1535-7163.MCT-13-1086","volume":"13","author":"K Dayekh","year":"2014","unstructured":"Dayekh, K. et al. Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors. Mol Cancer Ther 13, 2559\u20132571 (2014).","journal-title":"Mol Cancer Ther"},{"key":"BFsrep17523_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4046\/trd.2013.75.1.9","volume":"75","author":"HS Choi","year":"2013","unstructured":"Choi, H. S. et al. Autophagy Inhibition with Monensin Enhances Cell Cycle Arrest and Apoptosis Induced by mTOR or Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Cells. Tuberc Respir Dis (Seoul) 75, 9\u201317 (2013).","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"BFsrep17523_CR12","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1158\/1535-7163.MCT-10-0368","volume":"9","author":"K Ketola","year":"2010","unstructured":"Ketola, K., Vainio, P., Fey, V., Kallioniemi, O. & Iljin, K. Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells. Mol Cancer Ther 9, 3175\u20133185 (2010).","journal-title":"Mol Cancer Ther"},{"key":"BFsrep17523_CR13","first-page":"855","volume":"22","author":"WH Park","year":"2003","unstructured":"Park, W. H. et al. Monensin inhibits the growth of renal cell carcinoma cells via cell cycle arrest or apoptosis. Int J Oncol 22, 855\u2013860 (2003).","journal-title":"Int J Oncol"},{"key":"BFsrep17523_CR14","first-page":"377","volume":"22","author":"WH Park","year":"2003","unstructured":"Park, W. H., Kim, E. S., Jung, C. W., Kim, B. K. & Lee, Y. Y. Monensin-mediated growth inhibition of SNU-C1 colon cancer cells via cell cycle arrest and apoptosis. Int J Oncol 22, 377\u2013382 (2003).","journal-title":"Int J Oncol"},{"key":"BFsrep17523_CR15","first-page":"197","volume":"23","author":"WH Park","year":"2003","unstructured":"Park, W. H., Kim, E. S., Kim, B. K. & Lee, Y. Y. Monensin-mediated growth inhibition in NCI-H929 myeloma cells via cell cycle arrest and apoptosis. Int J Oncol 23, 197\u2013204 (2003).","journal-title":"Int J Oncol"},{"key":"BFsrep17523_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/ijc.10592","volume":"101","author":"WH Park","year":"2002","unstructured":"Park, W. H. et al. Monensin-mediated growth inhibition in acute myelogenous leukemia cells via cell cycle arrest and apoptosis. Int J Cancer 101, 235\u2013242 (2002).","journal-title":"Int J Cancer"},{"key":"BFsrep17523_CR17","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1046\/j.1365-2141.2002.03834.x","volume":"119","author":"WH Park","year":"2002","unstructured":"Park, W. H. et al. Monensin-mediated growth inhibition in human lymphoma cells through cell cycle arrest and apoptosis. Br J Haematol 119, 400\u2013407 (2002).","journal-title":"Br J Haematol"},{"key":"BFsrep17523_CR18","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/1535-7163.MCT-13-0625","volume":"13","author":"L Tumova","year":"2014","unstructured":"Tumova, L. et al. Monensin inhibits canonical Wnt signaling in human colorectal cancer cells and suppresses tumor growth in multiple intestinal neoplasia mice. Mol Cancer Ther 13, 812\u2013822 (2014).","journal-title":"Mol Cancer Ther"},{"key":"BFsrep17523_CR19","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.ygyno.2013.09.034","volume":"131","author":"RC Arend","year":"2013","unstructured":"Arend, R. C., Londono-Joshi, A. I., Straughn, J. M., Jr. & Buchsbaum, D. J. The Wnt\/beta-catenin pathway in ovarian cancer: a review. Gynecol Oncol 131, 772\u2013779 (2013).","journal-title":"Gynecol Oncol"},{"key":"BFsrep17523_CR20","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3892\/or.2013.2438","volume":"30","author":"JL Gao","year":"2013","unstructured":"Gao, J. L. et al. Ginseng saponin metabolite 20(S)-protopanaxadiol inhibits tumor growth by targeting multiple cancer signaling pathways. Oncol Rep 30, 292\u2013298 (2013).","journal-title":"Oncol Rep"},{"key":"BFsrep17523_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3892\/ijo.2010.858","volume":"38","author":"BC He","year":"2011","unstructured":"He, B. C. et al. Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt\/ss-catenin signaling. Int J Oncol 38, 437\u2013445 (2011).","journal-title":"Int J Oncol"},{"key":"BFsrep17523_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1124\/mol.110.068668","volume":"79","author":"BC He","year":"2011","unstructured":"He, B. C. et al. Tetrandrine inhibits Wnt\/beta-catenin signaling and suppresses tumor growth of human colorectal cancer. Mol Pharmacol 79, 211\u2013219 (2011).","journal-title":"Mol Pharmacol"},{"key":"BFsrep17523_CR23","doi-asserted-by":"publisher","first-page":"726","DOI":"10.2174\/1568009615666150629132157","volume":"15","author":"Z Liao","year":"2015","unstructured":"Liao, Z. et al. The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal Pathways. Curr Cancer Drug Targets 15, 726\u2013738 (2015).","journal-title":"Curr Cancer Drug Targets"},{"key":"BFsrep17523_CR24","doi-asserted-by":"publisher","first-page":"e0132666","DOI":"10.1371\/journal.pone.0132666","volume":"10","author":"Q Zhang","year":"2015","unstructured":"Zhang, Q. et al. TqPCR: A Touchdown qPCR Assay with Significantly Improved Detection Sensitivity and Amplification Efficiency of SYBR Green qPCR. PLoS One 10, e0132666 (2015).","journal-title":"PLoS One"},{"key":"BFsrep17523_CR25","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","volume":"25","author":"CL Arteaga","year":"2014","unstructured":"Arteaga, C. L. & Engelman, J. A. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25, 282\u2013303 (2014).","journal-title":"Cancer Cell"},{"key":"BFsrep17523_CR26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nrc3215","volume":"12","author":"M Pollak","year":"2012","unstructured":"Pollak, M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12, 159\u2013169 (2012).","journal-title":"Nat Rev Cancer"},{"key":"BFsrep17523_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.gendis.2014.10.004","volume":"2","author":"SK Denduluri","year":"2015","unstructured":"Denduluri, S. K. et al. Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis 2, 13\u201325 (2015).","journal-title":"Genes Dis"},{"key":"BFsrep17523_CR28","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70, 440\u2013446 (2010).","journal-title":"Cancer Res"},{"key":"BFsrep17523_CR29","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/0006-291X(91)91442-F","volume":"174","author":"RG Liteplo","year":"1991","unstructured":"Liteplo, R. G. Transformed rodent cells exhibit increased resistance to the carboxylic ionophores monensin and nigericin. Biochem Biophys Res Commun 174, 483\u2013488 (1991).","journal-title":"Biochem Biophys Res Commun"},{"key":"BFsrep17523_CR30","first-page":"623","volume":"52","author":"C Candiani","year":"1992","unstructured":"Candiani, C. et al. Blocking effect of human serum but not of cerebrospinal fluid on ricin A chain immunotoxin potentiation by monensin or carrier protein-monensin conjugates. Cancer Res 52, 623\u2013630 (1992).","journal-title":"Cancer Res"},{"key":"BFsrep17523_CR31","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/jnci\/85.4.292","volume":"85","author":"T Griffin","year":"1993","unstructured":"Griffin, T., Rybak, M. E., Recht, L., Singh, M., Salimi, A. & Raso, V. Potentiation of antitumor immunotoxins by liposomal monensin. J Natl Cancer Inst 85, 292\u2013298 (1993).","journal-title":"J Natl Cancer Inst"},{"key":"BFsrep17523_CR32","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1007\/s000180050214","volume":"54","author":"R Ippoliti","year":"1998","unstructured":"Ippoliti, R. et al. The effect of monensin and chloroquine on the endocytosis and toxicity of chimeric toxins. Cell Mol Life Sci 54, 866\u2013875 (1998).","journal-title":"Cell Mol Life Sci"},{"key":"BFsrep17523_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0168-3659(98)00174-6","volume":"59","author":"M Singh","year":"1999","unstructured":"Singh, M., Ferdous, A. J. & Jackson, T. L. Stealth monensin liposomes as a potentiator of adriamycin in cancer treatment. J Control Release 59, 43\u201353 (1999).","journal-title":"J Control Release"},{"key":"BFsrep17523_CR34","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1211\/002235703765951438","volume":"55","author":"MS Shaik","year":"2003","unstructured":"Shaik, M. S., Jackson, T. L. & Singh, M. Effect of monensin liposomes on the cytotoxicity of anti-My9-bR immunotoxin. J Pharm Pharmacol 55, 819\u2013825 (2003).","journal-title":"J Pharm Pharmacol"},{"key":"BFsrep17523_CR35","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3109\/10717544.2011.567309","volume":"18","author":"N Tyagi","year":"2011","unstructured":"Tyagi, N., Rathore, S. S. & Ghosh, P. C. Enhanced killing of human epidermoid carcinoma (KB) cells by treatment with ricin encapsulated into sterically stabilized liposomes in combination with monensin. Drug Deliv 18, 394\u2013404 (2011).","journal-title":"Drug Deliv"},{"key":"BFsrep17523_CR36","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1439-0442.2005.00728.x","volume":"52","author":"AC Souza","year":"2005","unstructured":"Souza, A. C. et al. Mitochondrial damage as an early event of monensin-induced cell injury in cultured fibroblasts L929. J Vet Med A Physiol Pathol Clin Med 52, 230\u2013237 (2005).","journal-title":"J Vet Med A Physiol Pathol Clin Med"},{"key":"BFsrep17523_CR37","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/j.1525-1438.2005.00137.x","volume":"15","author":"AN Gordon","year":"2005","unstructured":"Gordon, A. N. et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1\/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 15, 785\u2013792 (2005).","journal-title":"Int J Gynecol Cancer"},{"key":"BFsrep17523_CR38","doi-asserted-by":"publisher","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-05-0462","volume":"11","author":"RJ Schilder","year":"2005","unstructured":"Schilder, R. J. et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 11, 5539\u20135548 (2005).","journal-title":"Clin Cancer Res"},{"key":"BFsrep17523_CR39","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1471-2121-10-84","volume":"10","author":"BM Chung","year":"2009","unstructured":"Chung, B. M. et al. Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src. BMC Cell Biol 10, 84 (2009).","journal-title":"BMC Cell Biol"},{"key":"BFsrep17523_CR40","doi-asserted-by":"publisher","first-page":"e93608","DOI":"10.1371\/journal.pone.0093608","volume":"9","author":"N Wang","year":"2014","unstructured":"Wang, N. et al. Adenovirus-mediated efficient gene transfer into cultured three-dimensional organoids. PLoS One 9, e93608 (2014).","journal-title":"PLoS One"},{"key":"BFsrep17523_CR41","doi-asserted-by":"publisher","first-page":"e97316","DOI":"10.1371\/journal.pone.0097316","volume":"9","author":"N Wang","year":"2014","unstructured":"Wang, N. et al. The piggyBac Transposon-Mediated Expression of SV40 T Antigen Efficiently Immortalizes Mouse Embryonic Fibroblasts (MEFs). PLoS One 9, e97316 (2014).","journal-title":"PLoS One"},{"key":"BFsrep17523_CR42","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.3727\/096368914X681054","volume":"24","author":"JD Lamplot","year":"2015","unstructured":"Lamplot, J. D. et al. Reversibly Immortalized Mouse Articular Chondrocytes Acquire Long-Term Proliferative Capability while Retaining Chondrogenic Phenotype. Cell Transplant 24, 1053\u20131066 (2015).","journal-title":"Cell Transplant"},{"key":"BFsrep17523_CR43","doi-asserted-by":"publisher","first-page":"e94397","DOI":"10.1371\/journal.pone.0094397","volume":"9","author":"S Wen","year":"2014","unstructured":"Wen, S. et al. Characterization of constitutive promoters for piggyBac transposon-mediated stable transgene expression in mesenchymal stem cells (MSCs). PLoS One 9, e94397 (2014).","journal-title":"PLoS One"},{"key":"BFsrep17523_CR44","doi-asserted-by":"publisher","first-page":"e92908","DOI":"10.1371\/journal.pone.0092908","volume":"9","author":"C Zhao","year":"2014","unstructured":"Zhao, C. et al. Adenovirus-mediated gene transfer in mesenchymal stem cells can be significantly enhanced by the cationic polymer polybrene. PLoS One 9, e92908 (2014).","journal-title":"PLoS One"},{"key":"BFsrep17523_CR45","doi-asserted-by":"publisher","first-page":"274","DOI":"10.2174\/1568009614666140305105805","volume":"14","author":"R Li","year":"2014","unstructured":"Li, R. et al. Targeting BMP9-Promoted Human Osteosarcoma Growth by Inactivation of Notch Signaling. Curr Cancer Drug Targets, 14, 274\u2013285 (2014).","journal-title":"Curr Cancer Drug Targets"},{"key":"BFsrep17523_CR46","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/ijc.10719","volume":"102","author":"RC Haydon","year":"2002","unstructured":"Haydon, R. C. et al. Cytoplasmic and\/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 102, 338\u2013342 (2002).","journal-title":"Int J Cancer"},{"key":"BFsrep17523_CR47","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10585-005-0365-9","volume":"22","author":"HH Luu","year":"2005","unstructured":"Luu, H. H. et al. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis 22, 319\u2013329 (2005).","journal-title":"Clin Exp Metastasis"},{"key":"BFsrep17523_CR48","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.canlet.2005.02.015","volume":"229","author":"HH Luu","year":"2005","unstructured":"Luu, H. H. et al. Increased expression of S100A6 is associated with decreased metastasis and inhibition of cell migration and anchorage independent growth in human osteosarcoma. Cancer Lett 229, 135\u2013148 (2005).","journal-title":"Cancer Lett"},{"key":"BFsrep17523_CR49","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/labinvest.2008.98","volume":"88","author":"X Luo","year":"2008","unstructured":"Luo, X. et al. Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest 88, 1264\u20131277 (2008).","journal-title":"Lab Invest"},{"key":"BFsrep17523_CR50","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10585-009-9259-6","volume":"26","author":"Y Su","year":"2009","unstructured":"Su, Y. et al. Establishment and characterization of a new highly metastatic human osteosarcoma cell line. Clin Exp Metastasis 26, 599\u2013610 (2009).","journal-title":"Clin Exp Metastasis"},{"key":"BFsrep17523_CR51","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1038\/onc.2011.97","volume":"30","author":"Y Su","year":"2011","unstructured":"Su, Y. et al. Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma. Oncogene 30, 3907\u20133917 (2011).","journal-title":"Oncogene"},{"key":"BFsrep17523_CR52","first-page":"1288","volume":"8","author":"RC Haydon","year":"2002","unstructured":"Haydon, R. C. et al. Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin Cancer Res 8, 1288\u20131294 (2002).","journal-title":"Clin Cancer Res"},{"key":"BFsrep17523_CR53","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1158\/1078-0432.CCR-09-2499","volume":"16","author":"BC He","year":"2010","unstructured":"He, B. C. et al. Synergistic antitumor effect of the activated PPARgamma and retinoid receptors on human osteosarcoma. Clin Cancer Res 16, 2235\u20132245 (2010).","journal-title":"Clin Cancer Res"},{"key":"BFsrep17523_CR54","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.2106\/00004623-200308000-00017","volume":"85-A","author":"H Cheng","year":"2003","unstructured":"Cheng, H. et al. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am 85-A, 1544\u20131552 (2003).","journal-title":"J Bone Joint Surg Am"},{"key":"BFsrep17523_CR55","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1089\/scd.2008.0130","volume":"18","author":"Q Kang","year":"2009","unstructured":"Kang, Q. et al. A comprehensive analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation of mesenchymal progenitor cells. Stem Cells Dev 18, 545\u2013559 (2009).","journal-title":"Stem Cells Dev"},{"key":"BFsrep17523_CR56","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1038\/sj.gt.3302298","volume":"11","author":"Q Kang","year":"2004","unstructured":"Kang, Q. et al. Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther 11, 1312\u20131320 (2004).","journal-title":"Gene Ther"},{"key":"BFsrep17523_CR57","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/nprot.2007.135","volume":"2","author":"J Luo","year":"2007","unstructured":"Luo, J. et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc 2, 1236\u20131247 (2007).","journal-title":"Nat Protoc"},{"key":"BFsrep17523_CR58","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/gt.2014.40","volume":"21","author":"N Wu","year":"2014","unstructured":"Wu, N. et al. Overexpression of Ad5 precursor terminal protein accelerates recombinant adenovirus packaging and amplification in HEK-293 packaging cells. Gene Ther 21, 629\u2013637 (2014).","journal-title":"Gene Ther"},{"key":"BFsrep17523_CR59","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1159\/000354518","volume":"32","author":"Y Kong","year":"2013","unstructured":"Kong, Y. et al. Destabilization of Heterologous Proteins Mediated by the GSK3beta Phosphorylation Domain of the beta-Catenin Protein. Cell Physiol Biochem 32, 1187\u20131199 (2013).","journal-title":"Cell Physiol Biochem"},{"key":"BFsrep17523_CR60","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/jcmm.12097","volume":"17","author":"X Liu","year":"2013","unstructured":"Liu, X. et al. Cross-talk between EGF and BMP9 signalling pathways regulates the osteogenic differentiation of mesenchymal stem cells. J Cell Mol Med 17, 1160\u20131172 (2013).","journal-title":"J Cell Mol Med"},{"key":"BFsrep17523_CR61","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/jor.22427","volume":"31","author":"Y Wang","year":"2013","unstructured":"Wang, Y. et al. Noggin resistance contributes to the potent osteogenic capability of BMP9 in mesenchymal stem cells. J Orthop Res 31, 1796\u20131803 (2013).","journal-title":"J Orthop Res"},{"key":"BFsrep17523_CR62","doi-asserted-by":"publisher","first-page":"e82436","DOI":"10.1371\/journal.pone.0082436","volume":"8","author":"Y Gao","year":"2013","unstructured":"Gao, Y. et al. Crosstalk between Wnt\/beta-Catenin and Estrogen Receptor Signaling Synergistically Promotes Osteogenic Differentiation of Mesenchymal Progenitor Cells. PLoS One 8, e82436 (2013).","journal-title":"PLoS One"},{"key":"BFsrep17523_CR63","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1111\/j.1582-4934.2008.00569.x","volume":"13","author":"N Tang","year":"2009","unstructured":"Tang, N. et al. BMP9-induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt\/beta-catenin signaling. J Cell Mol Med 13, 2448\u20132464 (2009).","journal-title":"J Cell Mol Med"},{"key":"BFsrep17523_CR64","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1159\/000354508","volume":"32","author":"X Chen","year":"2013","unstructured":"Chen, X. et al. The E.-F., Hand Calcium-Binding Protein S100A4 Regulates the Proliferation, Survival and Differentiation Potential of Human Osteosarcoma Cells. Cell Physiol Biochem 32, 1083\u20131096 (2013).","journal-title":"Cell Physiol Biochem"},{"key":"BFsrep17523_CR65","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.canlet.2013.05.002","volume":"336","author":"GA Luther","year":"2013","unstructured":"Luther, G. A. et al. IGFBP5 Domains Exert Distinct Inhibitory Effects on the Tumorigenicity and Metastasis of Human Osteosarcoma. Cancer Lett 336, 222\u2013230 (2013).","journal-title":"Cancer Lett"},{"key":"BFsrep17523_CR66","doi-asserted-by":"publisher","first-page":"e113064","DOI":"10.1371\/journal.pone.0113064","volume":"9","author":"F Deng","year":"2014","unstructured":"Deng, F. et al. A Simplified and Versatile System for the Simultaneous Expression of Multiple siRNAs in Mammalian Cells Using Gibson DNA Assembly. PLoS One 9, e113064 (2014).","journal-title":"PLoS One"},{"key":"BFsrep17523_CR67","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.biomaterials.2014.11.007","volume":"39","author":"H Zhang","year":"2015","unstructured":"Zhang, H. et al. Canonical Wnt signaling acts synergistically on BMP9-induced osteo\/odontoblastic differentiation of stem cells of dental apical papilla (SCAPs). Biomaterials 39, 145\u2013154 (2015).","journal-title":"Biomaterials"},{"key":"BFsrep17523_CR68","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.7150\/ijms.6639","volume":"10","author":"M Li","year":"2013","unstructured":"Li, M. et al. Establishment and characterization of the reversibly immortalized mouse fetal heart progenitors. Int J Med Sci 10, 1035\u20131046 (2013).","journal-title":"Int J Med Sci"},{"key":"BFsrep17523_CR69","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1093\/nar\/gks596","volume":"40","author":"A Untergasser","year":"2012","unstructured":"Untergasser, A. et al. Primer3\u2013new capabilities and interfaces. Nucleic Acids Res 40, e115 (2012).","journal-title":"Nucleic Acids Res"},{"key":"BFsrep17523_CR70","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.gendis.2014.12.001","volume":"2","author":"X Chen","year":"2015","unstructured":"Chen, X. et al. Sustained high level transgene expression in mammalian cells mediated by the optimized piggyBac transposon system. Genes Dis 2, 96\u2013105 (2015).","journal-title":"Genes Dis"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep17523","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep17523.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep17523.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T19:22:16Z","timestamp":1672946536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep17523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,7]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12,22]]}},"alternative-id":["BFsrep17523"],"URL":"https:\/\/doi.org\/10.1038\/srep17523","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,7]]},"assertion":[{"value":"6 August 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17523"}}